Chemical-biology of natural products from medicinal plants for cancer therapy

Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs

Volumn , Issue , 2010, Pages 557-582

  Efferth, Thomas ^a   Wink, Michael ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84555198953     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0020-3_22     Document Type: Chapter

References (92)

1. Roth I, Lindorf H. South American medicinal plants. Berlin, Germany: Springer; 2002.
2. Schmeller T, Latz-Bruning B, Wink M. Biochemical activities of berberine, palmatine and sanguinarine mediating chemical defence against microorganisms and herbivores. Phytochemistry 1997;44:257-66. (Pubitemid 27087925)
3. Wink M. Allelochemical properties and the raison d'etre of alkaloids. In: Cordell G, editor. The alkaloids. New York: Academic Press; 1993. Vol. 43, pp. 1-118.
4. Wink M. Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective. Phytochemistry 2003;64:3-19. (Pubitemid 37101790)
5. Wink M. Plant secondary metabolism: Diversity, function and its evolution. Nat Prod Commun. 2008;3:1205-16.
6. Wink M. Ecological roles of alkaloids. In: Fattorusso E, Taglialatela-Scafati E, editors. Modern alkaloids: structure, isolation, synthesis, and biology. Weinheim: Wiley-VCH; 2008. pp. 3-24.
7. Wink, M. Evolutionary advantage and molecular modes of action of multicomponent mixtures in phytomedicine. Curr Drug Metab. 2008;9:996-1009.
8. Mothes K. Physiology of alkaloids. Annu Rev Plant Physiol. 1955;6:393-493.
9. Wink M. Plant breeding: Importance of plant secondary metabolites for protection against pathogens and herbivores. Theor Appl Genet. 1988;75;225-33.
10. Wink, M. Biochemistry of plant secondary metabolism. In: WinkM, editor. Annual plant review. Sheffield: Academic Press and CRC Press; 1999; Vol. 2, p. 1.
11. Wink M. Interference of alkaloids with neuroreceptors and ion channels. In: Atta-Ur-Rahman editor. Bioactive natural products. Amsterdam: Elsevier; 2000; Vol. 11, pp. 3-129.
12. Moed L, Shwayder TA, Chang MW Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol. 2001;137:1357-60. (Pubitemid 32954188)
13. Silverberg N. Pediatric molluscum contagiosum: optimal treatment strategies. Paediatr Drugs 2003;5:505-12. (Pubitemid 37046762)
14. Smolinski KN, Yan AC How and when to treat molluscum contagiosum and warts in children. Pediatr Ann. 2005;34:211-21. (Pubitemid 40396167)
15. Karras DJ, Farrell SE, Harrigan R.A., Henretig FM, Gealt L. Poisoning from "Spanish fly" (cantharidin). Am J Emerg Med. 1996;14:478-83.
16. Efferth T, Rauh R, Kahl S., Tomicic M, Bochzelt H, Tome M.E., Briehl MM, Bauer R, Kaina B. Molecular modes of action of cantharidin in tumor cells. Biochem Pharmacol. 2005;69:811-18. (Pubitemid 40248623)
17. Swingle M, Ni L, Honkanen RE Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol. 2007;365:23-38.
18. Rauh R, Kahl S, Boechzelt H., Bauer R, Kaina B, Efferth T. Molecular biology of cantharidin in cancer cells. Chin Med. 2007;2:8.
19. van Wyk B.E., Wink M. Medicinal plants of the world. Pretoria: Briza; 2004.
20. Wink M, van Wyk BE. Mind-altering and poisonous plants of the world. Pretoria: Briza; 2008.
21. Newman DJ, Cragg GM Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70:461-77. (Pubitemid 46595760)
22. Wink M. Importance of plant secondary metabolites for protection against insects and microbial infections. In: Carpinella C, Rai M, editors. Naturally occurring bioactive compounds: A new and safe alternative for control of pests and diseases. 2007;251-68.
23. Wink M. Bioprospecting: the search for bioactive lead structures from Nature. In: Kayser O, Quax W, editors. Medical plant biotechnology. From basic research to industrial applications. Weinheim: Wiley-VCH; 2007;1:97-116.
24. Wink M. Wie funktionieren Phytopharmaka? ZPhytother. 2005;26:262-70.
25. Reichenbach H, Hofle G. Discovery and development of the epothilones: a novel class of antineoplastic drugs. Drugs R D. 2008;9:1-10.
26. Muller H, Brackhagen O, Brunne R., Henkel T, Reichel F. Natural products in drug discovery. Ernst Schering Res Found Workshop 2000;32:205-16.
27. Lee ML, Schneider GJ Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. J Comb Chem. 2001;32:284-9.
28. Konkimalla VB, Efferth T. Anti-cancer natural product library from traditional chinese medicine. Comb Chem High Throughput Screen 2008;11:7-15.
29. Wink M. Molecular modes of action of cytotoxic alkaloids-from DNA intercalation, spindle poisoning, topoisomerase inhibition to apoptosis and multiple drug resistance. In: Cordell G, editors. The alkaloids. New York: Elsevier; 2007. Vol. 64, pp. 1-48.
30. Roberts MF, Wink M. Alkaloids: biochemistry, ecology, and medical applications. New York, NY: Plenum Press; 1998.
31. Wink M, Schmeller T, Latz-Bruning B. Modes of action of allelochemical alkaloids: interaction with neuroreceptors, DNA, and other molecular targets. J Chem Ecol. 1998;24:1881-1937. (Pubitemid 28546056)
32. Efferth T, Grassmann R. Impact of viral oncogenesis in responses to anticancer drugs and irradiation. Crit Rev Oncogen. 2000;11:165-87.
33. Volm M, Koomagi R, Mattern J., Efferth T. Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 2002;87:251-7.
34. Volm M, Koomagi R, Mattern J., Efferth T. Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin Cancer Res. 2002;8:1843-8. (Pubitemid 34633744)
35. Volm M, Koomagi R, Efferth T. Prediction of drug sensitivity and resistance of cancer by protein expression profiling. Cancer Genomics Proteomics 2004;1:157-66.
36. Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist Updat. 2005;8:85-97. (Pubitemid 40797959)
37. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets 2006;7:407-21. (Pubitemid 43744832)
38. Efferth T, Li PC, Konkimalla V.S., Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med. 2007;13:353-61. (Pubitemid 47126989)
39. Efferth T, Fu YJ, Zu Y.G., Schwarz G., Konkimalla VS, Wink M. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr Med Chem. 2007;14:2024-32. (Pubitemid 47578160)
40. Efferth T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin-from bench to bedside. Planta Med. 2007;73: 299-309. (Pubitemid 46910410)
41. Wink M. In: Cordell GA, editor. The alkaloids: chemistry and biology. San Diego, CA: Academic Press; 1993. Vol. 43, p. 1.
42. Wink M: Molecular modes of action of cytotoxic alkaloids: from DNA intercolation, spindle poisoning, to poisonerase inhibition to apoptosis and multiple drug resistance. Alkaloids Chem Biol. 2007;64:1-47.
43. Wink M, Schimmer O. Molecular modes of action of defensive secondary metabolites. In: Wink M, edition. Functions and biotechnology of plant secondary metabolites. Annual Plant Reviews. Wiley-Blackwelll; 2010. Vol. 39, pp. 21-161.
44. Christmann M, Tomicic MT, Roos W.P., Kaina B. Mechanisms of human DNA repair: an update. Toxicology 2003;193:31-4.
45. Schwarzl SM, Smith JC, Kaina B, Efferth T. Molecular modeling of O6-methylguanine-DNA methyltransferase mutant proteins encoded by single nucleotide polymorphisms. Int J Mol Med. 2005;16:553-7.
46. Konkimalla VS, Wang G, Kaina B., Efferth T. Microarray-based expression of DNA repair genes does not correlate with growth inhibition of cancer cells by natural products derived from traditional Chinese medicine. Cancer Genomics Proteomics 2008;5:79-84.
47. Li PC, Lam E, Roos W.P., Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res. 2008;68:4347-51.
48. Mazzini S, Bellucci MC, Mondelli R. Mode of binding of the cytotoxic alkaloid berberine with the double helix oligonucleotide d(AAGAATTCTT) (2). Bioorg Med Chem. 2003;11:505-14. (Pubitemid 36132227)
49. Garbett NC, Graves DE Extending nature's leads: the anticancer agent ellipticine. Curr Med Chem Anticancer Agents 2004;4:149-72. (Pubitemid 38404690)
50. Hofmann GA, Mattern MR Topoisomerase II in multiple drug resistance. Cytotechnology 1993;12:137-54.
51. Denny WA. Dual topoisomerase I/II poisons as anticancer drugs. Expert Opin Investig. Drugs. 1997;6:1845-51. (Pubitemid 27517588)
52. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem. 2000;7:39-58. (Pubitemid 30395448)
53. Dassonneville L, Bonjean K, De Pauw-Gillet MC, Colson P, Houssier C, Quetin-Leclercq J, Angenot L, Bailly C. Stimulation of topoisomerase II-mediated DNA cleavage by three DNA-intercalating plant alkaloids: cryp-tolepine, matadine, and serpentine. Biochemistry 1999;38:7719-26.
54. Neidle S, Parkinson GN Quadruplex DNA crystal structures and drug design. Biochimie 2008;90:1184-96.
55. Kim NW, Piatyszek MA, Prowse K.R., Harley CB, West MD, Ho PL, Coviello G.M., Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-15.
56. Read MA, Wood AA, Harrison J.R., Gowan SM, Kelland LR, Dosanjh HS, Neidle S. Molecular modeling studies on G-quadruplex complexes of telomerase inhibitors: structure-activity relationships. J Med Chem. 1999;42:4538-46. (Pubitemid 29530008)
57. Demeunynck M, Charmantray F, Martelli A. Interest of acridine derivatives in the anticancer chemotherapy. Curr Pharm Des. 2001;7:1703-24. (Pubitemid 32998334)
58. Sato N, Mizumoto K, Kusumoto M., Niiyama H, Maehara N, Ogawa T., Tanaka M. 9-Hydroxyellipticine inhibits telomerase activity in human pancreatic cancer cells. FEBS Lett. 1998;441:318-21. (Pubitemid 29027918)
59. Guittat L, Alberti P, Rosu F., Van Miert S, Thetiot E, Pieters L., Gabelica V, De Pauw E, Ottaviani A, Riou JF, Mergny JL. Interactions of cryptolepine and neocryptolepine with unusual DNA structures. Biochimie 2003;85:535-47. (Pubitemid 36626024)
60. Caprio V, Guyen B, Opoku-Boahen Y, Mann J., Gowan SM, Kelland LM, Read MA, Neidle S. A novel inhibitor of human telomerase derived from 10H-indolo[3,2-b]quinoline. Bioorg Med Chem Lett. 2000;10:2063-6.
61. Naasani I, Seimiya H, Yamori T., Tsuruo T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 1999;59:4004-11. (Pubitemid 29393569)
62. Warabi K, Matsunaga S, van Soest RW, Fusetani N. Dictyodendrins A-E, the first telomerase-inhibitory marine natural products from the sponge Dictyodendrilla verongiformis. J Org Chem. 2003;68:2765-70. (Pubitemid 36512651)
63. Zahler AM, Williamson JR, Cech T.R., Prescott DM Inhibition of telomer-ase by G-quartet DNA structures. Nature 1991;350:718-20. (Pubitemid 21912306)
64. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65-71. (Pubitemid 40081295)
65. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3:193-203. (Pubitemid 36565761)
66. Pellegrini F, Budman DR Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 2005;23(3):264-73. (Pubitemid 40770744)
67. Schulze-Bergkamen H., Krammer PH Apoptosis in cancer-implications for therapy. Semin Oncol. 2004;31:90-119. (Pubitemid 38209508)
68. Rosenkranz V, Wink M. Alkaloids induce programmed cell death in bloodstream forms of trypanosomes (Trypanosoma b. brucei). Molecules 2008;13:2462-73.
69. Rosenkranz V, Wink M. Induction of apoptosis by alkaloids in human promyelotic HL-60 cells. Z. Naturforsch, C: J Biosci. 2007;62c:458-66.
70. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta. 2007;1775:237-62. (Pubitemid 46899341)
71. Wang FP, Wang L, Yang J.S., Nomura M., Miyamoto K. Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bis-benzylisoquinoline alkaloids in mouse leukemia P388 cells. Biol Pharm Bull. 2005;28:1979-82. (Pubitemid 41437094)
72. Arora A, Seth K, Shukla Y. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis 2004;25:941-9. (Pubitemid 38886080)
73. Arora A, Seth K, Kalra N., Shukla Y. Modulation of P-glycoprotein- mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol. Toxicol Appl Pharmacol. 2005;202:237-43. (Pubitemid 40164277)
74. Efferth T, Olbrich A, Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol. 2002;64:617-23.
75. Efferth T, Sauerbrey A, Halatsch M.E., Ross DD, Gebhart E. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Nau-nyn Schmiedebergs Arch Pharmacol. 2003;367:56-67. (Pubitemid 36207682)
76. Efferth T, Sauerbrey A, Olbrich A., Gebhart E, Rauch P, Weber H.O., Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD, Funk JO. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003;64:382-94. (Pubitemid 36910002)
77. Efferth T, Oesch F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem Pharmacol. 2004;68:3-10. (Pubitemid 38746536)
78. Efferth T. Microarray-based prediction of cytotoxicity of tumor cells to cantharidin. Oncol Rep. 2005;13:459-63.
79. Efferth T, Chen Z, Kaina B., Wang G. Molecular determinants of response of tumor cells to berberine. Cancer Genomics Proteomics 2005;2:115-25.
80. Anfosso L, Efferth T, Albini A., Pfeffer U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J. 2006;6:269-78. (Pubitemid 44137954)
81. Efferth T, Miyachi H, Bartsch H. Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy. Cancer Genomics Proteomics 2007;4:81-91. (Pubitemid 46632029)
82. Efferth T, Kahl S, Paulus K., Adams M, Rauh R, Boechzelt H., Hao X, Kaina B, Bauer R. Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materia medica with activity against tumor cells. Mol Cancer Ther. 2008;7:152-61.
83. Konkimalla VB, Blunder M, Korn B., Soomro SA, Jansen H, Chang W, Posner G.H., Bauer R., Efferth T. Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. Nitric Oxide 2008;19:184-91.
84. Alley MC, Scudiero DA, Monks A, Hursey M.L., Czerwinski MJ, Fine DL, Abbott BJ, Mayo J.G., Shoemaker RH, Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetra-zolium assay. Cancer Res. 1988; 48:589-01.
85. Rubinstein LV, Shoemaker RH, Paull K.D., Simon RM, Tosini S, Skehan P, Scudiero D.A., Monks A., Boyd MR. Comparison of in vitro anticancer-drug- screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst. 1990;82:1113-18. (Pubitemid 20213251)
86. Wosikowski K, Schuurhuis D, Johnson K., Paull KD, Myers TG, Weinstein JN, Bates SE Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst. 1997;89:1505-15. (Pubitemid 27441175)
87. Scherf U, Ross DT, Waltham M, Smith L.H., Lee JK, Tanabe L, Kohn KW, Reinhold W.C., Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN. A gene expression database for the molecular pharmacology of cancer. Nat Genet. 2000;24:236-44. (Pubitemid 30132190)
88. Staunton JE, Slonim DK, Coller H.A., Tamayo P., Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES, Golub TR. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001;98:10787-92. (Pubitemid 32878698)
89. Russo D, Michelutti A, Melli C., Damiani D, Michieli MG, Candoni A, Zhou D.C., Marie JP, Zittoun R, Baccarani M. MDR-related P170-glyco-protein modulates cytotoxic activity of homoharringtonine. Leukemia 1995;9:513-16.
90. Efferth T, Davey M, Olbrich A., Rucker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1-or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis. 2002;28:160-8. (Pubitemid 34743750)
91. Efferth T, Sauerbrey A, Halatsch M.E., Ross DD, Gebhart E. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn Schmiedebergs Arch Pharmacol. 2003;367:56-67. (Pubitemid 36207682)
92. Cragg GM, Newman DJ Plants as a source of anti-cancer agents. J Ethno-pharmacol. 2005;100:72-9. (Pubitemid 41073525)